Search

Displaying results 3771 - 3780 of 4358 in total
  1. Drug

    MF-300

    go.drugbank.com/drugs/DB32060
    Investigational

    As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]

  2. Drug

    Salsalate

    go.drugbank.com/drugs/DB01399
    ApprovedInvestigational

    Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins.

  3. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    Some adults with this condition suffer from persistent, unrelenting discomfort and complications, such as joint pain, impaired mobility, tooth abscesses and hearing loss [L2346].

  4. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as

  5. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    [A253707] In February 2015, vonoprazan was first marketed in Japan for the treatment of acid-related disorders and as an adjunct to _Helicobacter pylori_ (_H. pylori_) eradication.

  6. Drug

    Choline salicylate

    go.drugbank.com/drugs/DB14006
    ApprovedNutraceutical

    Choline Salicylate is the choline salt of salicylic acid, used as an analgesic, antipyretic and antirheumatic. It relieves mild to moderate pain and reduce fever and inflammation or swelling.

  7. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    [L56135,L56136] This landmark decision followed designations as a Regenerative Medicine Advanced Therapy (RMAT) and Fast Track, marking the first-ever gene therapy approved to restore a neurosensory function

  8. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    [L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies

  9. Drug

    Flotufolastat F-18

    go.drugbank.com/drugs/DB17851
    ApprovedInvestigational

    Flotufolastat F-18 (18F-rhPSMA-7.3) is an 18F-labeled ligand that targets the prostate-specific membrane antigen (PSMA). In patients with recurrent prostate cancer that require localized treatment, the use of 18F-labeled ligands for posi...

  10. Drug

    Pegdinetanib

    go.drugbank.com/drugs/DB05931
    Investigational

    As a result, CT-322 blocks all known ligands for VEGFR-2.